Gregg Alton is former chief patient officer at Gilead Sciences, where he led patient outreach and engagement initiatives and efforts to facilitate access to medicines around the world. Mr. Alton joined Gilead in 1999 and held positions including general counsel, chief compliance officer, and secretary. He oversaw the company’s corporate and medical affairs functions, developing world access programs and commercial operations in emerging markets. Mr. Alton also served as interim chief executive officer. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP. Mr. Alton is a member of the President’s Advisory Council on HIV/Aids and serves on the boards of Corcept Therapeutics, Novavax, Inc., Enochian Biosciences, the Boys and Girls Clubs of Oakland, and the Hepatitis Fund. He is a member of the board of directors of Enochiam Biosciences and Collidion, Inc.
Former Chief Patient Officer, Gilead Sciences